- Home
- HOPE vs IRON Comparison
HOPE vs IRON Comparison
Compare HOPE & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOPE
- IRON
- Stock Information
- Founded
- HOPE 1986
- IRON 2017
- Country
- HOPE United States
- IRON United States
- Employees
- HOPE N/A
- IRON N/A
- Industry
- HOPE Major Banks
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- HOPE Finance
- IRON Health Care
- Exchange
- HOPE Nasdaq
- IRON Nasdaq
- Market Cap
- HOPE 1.3B
- IRON 1.4B
- IPO Year
- HOPE 1996
- IRON N/A
- Fundamental
- Price
- HOPE $10.16
- IRON $51.61
- Analyst Decision
- HOPE Buy
- IRON Strong Buy
- Analyst Count
- HOPE 3
- IRON 10
- Target Price
- HOPE $13.50
- IRON $93.40
- AVG Volume (30 Days)
- HOPE 741.0K
- IRON 381.1K
- Earning Date
- HOPE 07-28-2025
- IRON 08-07-2025
- Dividend Yield
- HOPE 5.51%
- IRON N/A
- EPS Growth
- HOPE N/A
- IRON N/A
- EPS
- HOPE 0.78
- IRON N/A
- Revenue
- HOPE $448,793,000.00
- IRON N/A
- Revenue This Year
- HOPE $17.54
- IRON N/A
- Revenue Next Year
- HOPE $12.05
- IRON N/A
- P/E Ratio
- HOPE $13.03
- IRON N/A
- Revenue Growth
- HOPE N/A
- IRON N/A
- 52 Week Low
- HOPE $8.83
- IRON $30.82
- 52 Week High
- HOPE $14.54
- IRON $68.73
- Technical
- Relative Strength Index (RSI)
- HOPE 49.52
- IRON 56.99
- Support Level
- HOPE $9.98
- IRON $48.87
- Resistance Level
- HOPE $10.69
- IRON $54.13
- Average True Range (ATR)
- HOPE 0.21
- IRON 2.31
- MACD
- HOPE -0.02
- IRON 0.07
- Stochastic Oscillator
- HOPE 39.77
- IRON 67.64
About HOPE Hope Bancorp Inc.
Hope Bancorp Inc is a bank holding company engaged in providing financial services. It offers core business banking products for small and medium-sized businesses and individuals. Services offered by the bank include online banking, mobile banking, mortgage loans, credit cards, investment and wealth management services and other banking services.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.